These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 11956086)

  • 1. A mutation hot spot in the Bcrp1 (Abcg2) multidrug transporter in mouse cell lines selected for Doxorubicin resistance.
    Allen JD; Jackson SC; Schinkel AH
    Cancer Res; 2002 Apr; 62(8):2294-9. PubMed ID: 11956086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
    Allen JD; Van Dort SC; Buitelaar M; van Tellingen O; Schinkel AH
    Cancer Res; 2003 Mar; 63(6):1339-44. PubMed ID: 12649196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Jonker JW; Smit JW; Brinkhuis RF; Maliepaard M; Beijnen JH; Schellens JH; Schinkel AH
    J Natl Cancer Inst; 2000 Oct; 92(20):1651-6. PubMed ID: 11036110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
    Honjo Y; Hrycyna CA; Yan QW; Medina-Pérez WY; Robey RW; van de Laar A; Litman T; Dean M; Bates SE
    Cancer Res; 2001 Sep; 61(18):6635-9. PubMed ID: 11559526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.
    Allen JD; Brinkhuis RF; Wijnholds J; Schinkel AH
    Cancer Res; 1999 Sep; 59(17):4237-41. PubMed ID: 10485464
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flavonoids chrysin and benzoflavone, potent breast cancer resistance protein inhibitors, have no significant effect on topotecan pharmacokinetics in rats or mdr1a/1b (-/-) mice.
    Zhang S; Wang X; Sagawa K; Morris ME
    Drug Metab Dispos; 2005 Mar; 33(3):341-8. PubMed ID: 15608138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells.
    Kim M; Turnquist H; Jackson J; Sgagias M; Yan Y; Gong M; Dean M; Sharp JG; Cowan K
    Clin Cancer Res; 2002 Jan; 8(1):22-8. PubMed ID: 11801536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
    Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
    Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug resistance genes in infant acute lymphoblastic leukemia: Ara-C is not a substrate for the breast cancer resistance protein.
    Stam RW; van den Heuvel-Eibrink MM; den Boer ML; Ebus ME; Janka-Schaub GE; Allen JD; Pieters R
    Leukemia; 2004 Jan; 18(1):78-83. PubMed ID: 14574327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential inhibition of murine Bcrp1/Abcg2 and human BCRP/ABCG2 by the mycotoxin fumitremorgin C.
    González-Lobato L; Real R; Prieto JG; Alvarez AI; Merino G
    Eur J Pharmacol; 2010 Oct; 644(1-3):41-8. PubMed ID: 20655304
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sex-dependent expression and activity of the ATP-binding cassette transporter breast cancer resistance protein (BCRP/ABCG2) in liver.
    Merino G; van Herwaarden AE; Wagenaar E; Jonker JW; Schinkel AH
    Mol Pharmacol; 2005 May; 67(5):1765-71. PubMed ID: 15722455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.
    Duan Z; Choy E; Jimeno JM; Cuevas Cdel M; Mankin HJ; Hornicek FJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1121-9. PubMed ID: 18828019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
    Allen JD; van Loevezijn A; Lakhai JM; van der Valk M; van Tellingen O; Reid G; Schellens JH; Koomen GJ; Schinkel AH
    Mol Cancer Ther; 2002 Apr; 1(6):417-25. PubMed ID: 12477054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells.
    Brooks TA; O'Loughlin KL; Minderman H; Bundy BN; Ford LA; Vredenburg MR; Bernacki RJ; Priebe W; Baer MR
    Invest New Drugs; 2007 Apr; 25(2):115-22. PubMed ID: 17072745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The bioflavonoid kaempferol is an Abcg2 substrate and inhibits Abcg2-mediated quercetin efflux.
    An G; Gallegos J; Morris ME
    Drug Metab Dispos; 2011 Mar; 39(3):426-32. PubMed ID: 21139040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single amino acid substitutions in the transmembrane domains of breast cancer resistance protein (BCRP) alter cross resistance patterns in transfectants.
    Miwa M; Tsukahara S; Ishikawa E; Asada S; Imai Y; Sugimoto Y
    Int J Cancer; 2003 Dec; 107(5):757-63. PubMed ID: 14566825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.